Who are (F) RH-V14's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eporatio, Mircera, Silapo, Aranesp, Neorecormon, Epogen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/f-rh-v14.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

(F) RH-V14 — Competitive Intelligence Brief

(F) RH-V14 ((F) RH-V14) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: erythropoiesis-stimulating agent. Area: Hematology.

marketed erythropoiesis-stimulating agent erythropoietin receptor Hematology Small molecule Live · refreshed every 30 min

Target snapshot

(F) RH-V14 ((F) RH-V14) — National Taiwan University Hospital. RH-V14 is a recombinant human erythropoietin used to stimulate erythropoiesis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
(F) RH-V14 TARGET	(F) RH-V14	National Taiwan University Hospital	marketed	erythropoiesis-stimulating agent	erythropoietin receptor
Eporatio	EPOETIN THETA		marketed		Erythropoietin receptor	2009-01-01
Mircera	METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	Hoffman-La Roche	marketed		erythropoietin receptor	2007-01-01
Silapo	EPOETIN ZETA	Hospira UK Limited	marketed		Erythropoietin receptor	2007-01-01
Aranesp	DARBEPOETIN ALFA	Amgen	marketed	Erythropoiesis-stimulating Agent [EPC]	Erythropoietin receptor	2001-01-01
Neorecormon	EPOETIN BETA	Roche Registration Limited	marketed		Erythropoietin receptor	1997-01-01
Epogen	EPOETIN ALFA	Amgen	marketed	Erythropoiesis-stimulating Agent	Erythropoietin receptor	1989-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (erythropoiesis-stimulating agent class)

American Regent, Inc. · 1 drug in this class
Genexine, Inc. · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Mathew S. Maurer · 1 drug in this class
National Taiwan University Hospital · 1 drug in this class
Sandoz · 1 drug in this class
Sunnybrook Health Sciences Centre · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). (F) RH-V14 — Competitive Intelligence Brief. https://druglandscape.com/ci/f-rh-v14. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab